glp-1 cardiovascular outcomes 2025 news Beyond Blood Sugar: A Scoping Review of Receptor Agonists in Care GLP-1 studies add to growing

Comprehensive Assessment Reviewing your medical history, weight loss goals, and any existing health conditions

Retatrutide is a novel peptide studied for metabolic research

Rapid weight loss or prolonged fasting periods due to appetite suppression is likely to be associated with a higher risk of hypoglycemia, and therefore, should be avoided in patients with T1D

Outcomes: AUD diagnosis and/or alcohol-related hospitalization, preferentially reported as hazard ratios (HRs) with 95% confidence intervals (CIs)

The usage for treating obesity is subcutaneous injection once a week

JourneyLite patients receive education, nutritional guidance, follow-up care, and long-term support designed to help them use their procedure effectively for years to come